arrow
F

Francesco Passamonti

university of milan
H指数:90
被引数:3.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immune and cellular determinants of response to HMA-venetoclax regimens in acute myeloid leukemia

免疫和细胞学因素对急性髓系白血病中HMA-venetoclax方案疗效的影响

2026-10-140
OAAI
Role of direct-acting antivirals in people with HIV-associated non-Hodgkin lymphoma and concomitant HCV infection: A study on behalf of the Fondazione Italiana Linfomi

直接抗病毒药物在合并HCV感染的HIV相关非霍奇金淋巴瘤患者中的作用:意大利淋巴瘤基金会研究

2026-09-060
PRE
The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study

赖氨酸特异性去甲基化酶1(LSD1)抑制剂bomedemstat在骨髓纤维化中的应用:一项1/2期研究的结果

2026-05-020
OAAI
Health Care Utilization Databases obtained from health system inform outcome for ruxolitinib treatment in patients with myelofibrosis

来自卫生系统信息的数据库显示,ruxolitinib治疗对骨髓纤维化患者的影响结果。

2026-02-240
OAAI
European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis

欧洲白血病网络联盟(European LeukemiaNet)关于新药在骨髓纤维化中安全性和有效性评估的标准

2025-11-240
OAAI
Viral respiratory infections in patients with hematological diseases over 10 years: epidemiology and impact on disease severity

10年来血液病患者的病毒性呼吸道感染:流行病学及其对疾病严重程度的影响

2025-10-010
PRE
Treatment persistence and overall survival in myelofibrosis treated with ruxolitinib were not affected by the covid-19 pandemic, despite the reduced starting dose: Analysis of AIFA registries

尽管起始剂量有所减少,接受鲁索利替尼治疗的骨髓纤维化患者的治疗持续性和总生存期并未受到COVID-19大流行的影响:意大利药品管理局登记数据分析

2025-09-200
OA
Characterization of Breakthrough Hemolysis in Patients With Paroxysmal Nocturnal Hemoglobinuria: An International Multicenter Experience

阵发性夜间血红蛋白尿症患者突破性溶血的特征:一项国际多中心经验

2025-08-110
OAAI
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design

探讨真性红细胞增多症的血栓栓塞危险因素:从现有证据到PROSPERO研究设计

2025-07-180
OA
Clinical outcomes of high-risk patients with polycythemia vera after suboptimal response to first-line therapy who switched to ruxolitinib versus nonswitchers: results from the PV-Switch study

真性红细胞增多症高风险患者在接受一线治疗效果不佳后切换至鲁索利替尼治疗与非切换者的临床结局比较:PV-Switch研究的结果

2025-07-040
OA
BLAST: a globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia

BLAST:一种适用于全球范围且分子上具有多样性的慢性髓系单核细胞白血病患者生存模型

Blood
IF23.1
2025-05-090
PRE